DUBLIN – Glycosylation specialist Glycotope GmbH is getting €80 million (US$90 million) up front as part of a licensing and equity investment deal with Octapharma AG covering a preclinical portfolio of blood coagulation factors. Read More
Taurx Therapeutics Ltd., a company advancing a potentially powerful prodrug of methylthioninium chloride for the potential prevention of neurodegenerative diseases, has closed a $135 million equity financing that will support completion and analysis of phase III trials of the tau aggregation inhibitor (TAI), called LMT-X, in Alzheimer's disease (AD) and frontotemporal dementia. Read More
"Proceed with caution" is the advice the U.S. Patent and Trademark Office (PTO) handed Congress in a report on the availability of confirmatory gene-based testing. Read More
Not done with the old, but in with the new. That seemed the drumbeat for Vertex Pharmaceuticals Inc., which looked to squeeze out every bit of commercial opportunity for its cystic fibrosis (CF) drug, Kalydeco (ivacaftor), even as it introduced the next generation of CF candidates. Read More
Nusirt Biopharma Inc., of Nashville, Tenn., has raised a total of $10 million in a series C round to fund a planned trial to determine if its technology has potential to become a new treatment for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Read More
Boehringer Ingelheim Pharmaceuticals Inc., of Ingelheim, Germany, reported phase II data showing its biologic BI655066 demonstrated superior efficacy over ustekinumab. Read More
Blinkbio Inc., of Jupiter, Fla., entered a collaboration agreement with Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, in the discovery research area, in order to accelerate the optimization of prototype leads discovered in the company's self-assembling dimer program targeting the inhibition of Protein-Protein Interactions. Read More
